PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome

Nervous System Disease Clinical Trial

Official title:

PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of Mccune-Albright Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02743377
• Other study ID #: 160093
• Secondary ID: 16-M-0093
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: April 4, 2018
• Est. completion date: May 19, 2020

Study information

• Verified date: May 19, 2020
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background:

McCune-Albright Syndrome (MAS) is a disorder that affects the bones, skin, and some hormone-producing tissues. It is associated with a mutation in a gene. This gene affects enzymes in the brain and body. Researchers want to learn more about one of these enzymes, Phosphodiesterase 4 (PDE4), in people with MAS.

Objective:

To see if people with MAS have higher levels of PDE4 than people without MAS.

Eligibility:

People ages 18 and older who have MAS and participated in protocol 98-D-0145, Screening and Natural History of Patients with Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome. Healthy adult volunteers are also needed.

Design:

This study requires 1 to 4 outpatient visits to the NIH Clinical Center. Some visits may take place on the same day.

Participants with MAS will be screened with medical history and physical exam. They will have blood and urine tests.

Participants will have a magnetic resonance imaging scan.

Participants will have a full body positron emission tomography (PET) scan. A small amount of a radioactive chemical, [11C](R)-rolipram, will be given through an intravenous tube.

Participants will have a brain PET scan with [11C](R)-rolipram. For this, a thin plastic tube will also be put into an artery at their wrist or elbow crease area.

For the scans, participants will lie on a bed that slides in and out of a scanner. They may wear a plastic mask to hold their head in place. They will have blood drawn.

Participants with MAS will be interviewed about their thinking and mood. They may complete questionnaires about how they feel or think.

Description:

Objective: McCune-Albright syndrome (MAS) is a mosaic disease arising from early embryonic somatic activating mutations of GNAS, which encodes the 3 <=, 5 <=-cyclic adenosine monophosphate (cAMP) pathway-associated G-protein, Gs . Constitutive activation of Gs leads to increased cAMP signaling in brain, as well as in peripheral organs, particularly bones. Although subjects with MAS show psychiatric and neurological symptoms, few studies have attempted to assess brain changes in these individuals. This protocol seeks to study changes in the cAMP cascade both in brain and peripheral organs of individuals with MAS using [11C](R)-rolipram PET, which binds to phosphodiesterase 4 (PDE4) and reflects cAMP cascade activity.

Study population: Participants will include 20 subjects with MAS and 15 healthy subjects group-matched to MAS subjects for age and gender. Both MAS subjects and healthy controls will have one or two PET scans: one whole body and one brain scan. We expect about 10 brain and 10 whole body scan to be performed in each group.

Design: Subjects with MAS will be recruited from participants in 98-D-0145 Screening and Natural History of Patients with Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome (PI: Alison M. Boyce, MD). Only participants in protocol (98-D-0145) who provided self-consent without a legally authorized representative will be recruited. Brain PET scans will be performed by measuring metabolite-corrected arterial input function. No venous blood sampling will be performed for whole body scans.

Outcome measures: The primary outcome measure will be obtained in brain scans as the amount of radioligand binding quantified as distribution volume (Vt). Calculated from both brain and plasma data, Vt reflects rolipram binding to PDE4, corrected for any individual differences in metabolism of the radioligand or regional blood flow in brain. The secondary outcome measure will be obtained in whole body scans as area under the curve (AUC) of radioactivity expressed as standard uptake value (SUV). SUV is calculated by normalizing radioactivity in PET images to injection activity and body weight. Vt in brain will be compared between subjects with MAS and healthy controls. AUC will be compared within-subjects with MAS between areas of craniofacial fibrous dysplasia and adjacent unaffected bone. AUC of whole body scans will also be compared between subjects with MAS and healthy controls. We hypothesize that subjects with MAS will show greater rolipram binding than healthy controls in brain regions, as well as greater rolipram uptake in bones affected by fibrous dysplasia than in unaffected bones.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: May 19, 2020
• Est. primary completion date: October 23, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

• INCLUSION CRITERIA:

Subjects with MAS:

• At least 18 years of age

• Able to provide self-consent

• Diagnosed with MAS under 98-D-0145.

• Have craniofacial fibrous dysplasia

Healthy Subjects:

• At least 18 years of age.

• Healthy based on medical history and physical examination.

EXCLUSION CRITERIA:

Subjects with MAS:

• Serious medical conditions, which may interfere with study procedures. Such conditions include but not limited to significant bone abnormalities in wrist areas of both arms, which makes it difficult to place a radial arterial line, clinically marked dysfunction of liver or kidney, which may delay clearance of [(11)C](R)-rolipram.

• Clinically significant laboratory abnormalities not linked to endocrine abnormalities but that may interfere with the PET measurement or affect safety of the participant during this study.

• Positive HIV test.

• Head trauma resulting in a period of unconsciousness lasting longer than one hour.

• Metallic foreign bodies that would be affected by the magnetic resonance imaging (MRI) magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan.

• Recent research-related exposure to radiation (i.e., PET from other research) that, when combined with this study, would be above the allowable limits.

• Inability to lie flat on camera bed for about two and a half hours.

• Pregnancy or breastfeeding.

• NIMH employees/staff and their immediate family members will be excluded from the study per NIMH policy.

Healthy Subjects:

• Serious medical conditions, which may interfere with study procedures. Such conditions include but not limited to clinically marked dysfunction of liver or kidney, which may delay clearance of [(11)C](R)-rolipram.

• Clinically significant laboratory abnormalities that may interfere with the PET measurement or affect safety of the participant during this study.

• Personal history of any DSM Axis I disorder.

• Positive HIV test.

• Head trauma resulting in a period of unconsciousness lasting longer than one hour.

• Metallic foreign bodies that would be affected by the MRI magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan.

• Recent research-related exposure to radiation (i.e., PET from other research) that, when combined with this study, would be above the allowable limits.

• Inability to lie flat on camera bed for about two and a half hours.

• Pregnancy or breastfeeding.

• Current substance use disorder based on DSM.

• NIMH employees/staff and their immediate family members will be excluded from the study per NIMH policy.

Related Conditions & MeSH terms

• Nervous System Disease
• Nervous System Diseases

Intervention

Other:
• Brain PET Imaging with 11C Rolipram
Brain PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan

Drug:
• Whole Body PET Baseline with 11C Rolipram
Whole Body Baseline PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan
• Whole Body PET Blocked with Roflumilast
Whole Body PET Imaging scan after blockade with Roflumilast 500 mcg PO, given 1-2 hours prior to start of scan

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Bladder	Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.	120 minutes
Primary	Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) -Gallbladder	Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.	120 minutes
Primary	Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Heart	Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.	120 minutes
Primary	Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Kidneys	Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls.	120 minutes
Primary	Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Liver	Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls	120 minutes
Primary	Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Lungs	Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls	120 minutes
Primary	Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) -Spleen	Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls	120 minutes
Primary	Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Stomach	Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls	120 minutes
Primary	Whole Brain Total Distribution Volume (VT)	Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the brain of patients with McCune-Albright Syndrome (MAS) compared to healthy controls	90 minutes
Primary	MAS Affected Bone SUV AUC(60-120min) at Baseline	To assess whether uptake in dysplastic bone reflects parent radioligand binding to the enzyme or merely accumulation of radiometabolites	120 minutes
Primary	MAS Affected Bone SUV AUC(60-120min) - Blocked	To assess whether uptake in dysplastic bone reflects parent radioligand binding to the enzyme or merely accumulation of radiometabolites	120 minutes
Secondary	MAS Affected Bone SUV AUC(60-120min) - for Baseline and Blocked Subjects With MAS	Determine if PDE4 levels are different in areas of fibrous dysplasia as compared to unaffected bones in patients with MAS	120 minutes
Secondary	Normal Bone SUV AUC (60-120min) - for Healthy Controls	Determine if PDE4 levels are different in areas of fibrous dysplasia as compared to unaffected bones in patients with MAS	120 minutes after the start of the scan

External Links

•   NIH Clinical Center Detailed Web Page